Speed of haemoglobin response in patients with cancer: A review of the erythropoietic proteins

Supportive Care in Cancer

Volumn 15, Issue 6, 2007, Pages 603-611

  Oberhoff, Carsten ^a  

^a Marienhospital Altenessen ^*  (Germany)

Author keywords

Anaemia; Cancer; Epoetin; Erythropoietin; Haemoglobin

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL TRIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANEMIA; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 34447132393     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0191-x     Document Type: Review

References (54)

1. ASHP (1999) Therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 56:729-764
2. Barrett-Lee PJ, Bailey NP, O'Brien ME, Wager E (2000) Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82:93-97
3. Berger AM, VonEssen S, Kuhn BR et al (2003) Adherence, sleep, and fatigue outcomes after adjuvant breast cancer chemotherapy: results of a feasibility intervention study. Oncol Nurs Forum 30:513-522
4. Bohlius J, Wilson J, Seidenfeld J et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708-714
5. Boogaerts M, Coiffier B, Kainz C and the Epoetin β QoL Working Group (2003) Impact of epoetin β on quality of life in patients with malignant disease. Br J Cancer 88:988-995
6. Boogaerts M, Oberhoff C, ten Bokkel Huinink W, Nowrousian MR, Hayward C, Burger H-U (2006) Epoetin Beta (NeoRecormon®) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis. Anticancer Res 26:479-484
7. Campos SM, Duh MS, Lefebvre P, Rosberg J (2005) Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw 3:807-816
8. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122:386-393
9. Cheung WK, Danneman B, Wacholtz M, Lau H, Miller D (2004) Pharmacokinetics (PK) and pharmacodynamics (PD) of epoetin alfa in anemic cancer patients receiving cycling chemotherapy. Blood 104:111b (abstract 4101)
10. Coiffier B (2004) Epoetin once weekly in anaemic patients with cancer. Br J Haematol 125:100-101
11. Coiffier B, Guastalla J-P, Pujade-Lauraine E, Bastit P; for the Anemia Study Group (2001) Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 37:1617-1623
12. Coiffier B, Milpied N, Facon T, Beris P (2004) Epoetin beta (NeoRecormon) once weekly or three-times weekly produces a rapid haemoglobin response in anaemic patients with lymphoproliferative malignancies. Hematol J 5 (Suppl 2):S189 (abstract 551)
13. Coiffier B, Boogaerts M, Aapro M, Hayward C, Burger H-U (2005) Risk factors for thromboembolic events with NeoRecormon® (epoetin beta): a meta-analysis of controlled clinical trials. Ann Oncol 16(Suppl 5):v214 (abstract 612)
14. Darbepoetin alfa Summary of Product Characteristics (2006) Annex 1, p. 8. (http://www.emea.eu.int/humandocs/Humans/EPAR/aranesp/aranesp.htm) URL visited 7th September 2006
15. Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412-3425
16. Dillon E, Kelly J, AIFC (2003) The status of cancer fatigue on the Island of Ireland: AIFC professional and interim patient surveys. Oncologist 8(Suppl 1):22-26
17. Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84(Suppl 1):3-10
18. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15:1218-1234
19. Glaspy JA, Jadeja JS, Justice G et al (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87:268-276
20. Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB (2003) A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 97:1312-1320
21. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616-1634
22. Halstenson CE, Macres M, Katz SA et al (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50:702-712
23. Haselbeck A (2003) Epoetins: differences in their relevance to immunogenicity. Curr Med Res Opin 19:430-432
24. Heatherington AC, Schuller J, Mercer AJ (2001) Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 84(Suppl 1):11-16
25. Heatherington AC, Dittrich C, Sullivan JT, Rossi G, Schueller J (2006) Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. Clin Pharmacokinet 45:199-211
26. Hedenus M, Hansen S, Taylor K et al, Darbepoetin Alfa 990114 Study Group (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119:79-86
27. Hedenus M, Adriansson M, San Miguel J et al, Darbepoetin Alfa 20000161 Study Group (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122:394-403
28. Hudis CA, Van Belle S, Chang J, Muenstedt K (2004) rHuEPO and treatment outcomes: the clinical experience. Oncologist 9(Suppl 5):55-69
29. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J (2003) Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 101:91-96
30. Landy S (2004) Migraine throughout the life cycle: treatment through the ages. Neurology 62:S2-S8
31. Leyland-Jones B, BEST Investigators and Study Group (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459-460
32. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, for the Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874
33. Ludwig H, Van Belle S, Barrett-Lee P et al (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293-2306
34. Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD (1989) Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1:425-427
35. Macdougall IC, Gray SJ, Elston O et al (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392-2395
36. Morreale A, Plowman B, DeLattre M, Boggie D, Schaefer M (2004) Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 20:381-395
37. Ng T, Marx G, Littlewood T, Macdougall I (2003) Recombinant erythropoietin in clinical practice. Postgrad Med J 79:367-376
38. Nowrousian MR, Oberhoff C, Morère JF, Monfardini S, Hayward C, Burger H-U (2005) Speed of response to epoetin beta in patients with solid tumours undergoing chemotherapy: results of a meta-analysis. Eur J Cancer (Suppl 3):378 (abstract 1310)
39. Oberhoff C, Neri B, Amadori D et al (1998) Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 9:255-260
40. Österborg A, Brandberg Y, Molostova V et al, for the Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20:2486-2494
41. Pujade-Lauraine E, Topham C (2005) Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins. Oncology 68:122-129
42. Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA (2005) Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. Curr Med Res Opin 21:1527-1533
43. Rosberg J, Lefebvre P, Fastenau J, Decter A (2003) Clinical significance of a ≥1 gram/deciliter (g/dL) rise in hemoglobin (Hb) at week 4 (early response) or at week 8 during epoetin alfa (EPO) treatment. Blood 102:510b (abstract 2777)
44. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM (2004) The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 27:185-190
45. Ruffer JU (2003) Tumor-related fatigue-an underestimated problem. Onkologie 26:423-424
46. Smith RE Jr, Tchekmedyian NS, Chan D et al (2003) A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 88:1851-1858
47. Storring PL (1992) Assaying glycoprotein hormones-the influence of glycosylation on immunoreactivity. Trends Biotechnol 10:427-432
48. Storring PL, Tiplady RJ, Gaines Das RE et al (1998) Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100:79-89
49. Takeuchi M, Kobata A (1991) Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology 1:337-346
50. Vansteenkiste J, Pirker R, Massuti B et al, Aranesp 980297 Study Group (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1120
51. Visovsky C, Schneider SM (2003) Cancer-related fatigue. Online J Issues Nurs 8:1-23
52. Vogelzang NJ, Breitbart W, Cella D et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34(Suppl 2):4-12
53. Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D (2005) Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 10:642-650
54. Williamson LM, Lowe S, Love EM et al (1999) Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ 319:16-19